These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35143848)

  • 61. Mechanisms of action of metformin with special reference to cardiovascular protection.
    Zilov AV; Abdelaziz SI; AlShammary A; Al Zahrani A; Amir A; Assaad Khalil SH; Brand K; Elkafrawy N; Hassoun AAK; Jahed A; Jarrah N; Mrabeti S; Paruk I
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3173. PubMed ID: 31021474
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H; Nester W; Elgendy IY; Saad M
    Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes.
    Choxi R; Roy S; Stamatouli A; Mayer SB; Jovin IS
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):187-199. PubMed ID: 32306789
    [No Abstract]   [Full Text] [Related]  

  • 67. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
    Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
    JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
    [TBL] [Abstract][Full Text] [Related]  

  • 68. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection.
    Bertoccini L; Baroni MG
    Adv Exp Med Biol; 2021; 1307():193-212. PubMed ID: 32034729
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.
    Lim LL; Chow E; Chan JCN
    Nat Rev Endocrinol; 2023 Mar; 19(3):151-163. PubMed ID: 36446898
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [The position of SGLT2 inhibitors in current medicine].
    Prázný M
    Vnitr Lek; 2020; 66(2):82-88. PubMed ID: 32942881
    [TBL] [Abstract][Full Text] [Related]  

  • 71. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
    Karagiannis T; Tsapas A; Athanasiadou E; Avgerinos I; Liakos A; Matthews DR; Bekiari E
    Diabetes Res Clin Pract; 2021 Apr; 174():108737. PubMed ID: 33705820
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Diabetes medications and cardiovascular disease: at long last progress.
    Lupsa BC; Inzucchi SE
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916
    [TBL] [Abstract][Full Text] [Related]  

  • 74. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes.
    Ferraro RA; Nass CM; Dudum R; Blumenthal RS; Sarkar S
    Am J Med; 2019 Sep; 132(9):1027-1031. PubMed ID: 30904510
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
    Schernthaner G; Shehadeh N; Ametov AS; Bazarova AV; Ebrahimi F; Fasching P; Janež A; Kempler P; Konrāde I; Lalić NM; Mankovsky B; Martinka E; Rahelić D; Serafinceanu C; Škrha J; Tankova T; Visockienė Ž
    Cardiovasc Diabetol; 2020 Oct; 19(1):185. PubMed ID: 33097060
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
    Packer M
    Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
    [No Abstract]   [Full Text] [Related]  

  • 77. [New and old glucose lowering drugs; a state-of-the-art review].
    IJzerman RG; Vrijlandt PJWS
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201636
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
    Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
    Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
    Anderson S; Cotiguala L; Tischer S; Park JM; McMurry K
    Ann Pharmacother; 2021 Apr; 55(4):496-508. PubMed ID: 32795145
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
    Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
    Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.